Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) Stock Price, Trades & News

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	2.36
Equity-to-Asset	0.53
Debt-to-Equity	0.06
Debt-to-EBITDA	0.22
Interest Coverage	19.16
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.53	Distress Grey Safe
Beneish M-Score	-2.31	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	13.5
	3-Year EBITDA Growth Rate	32.1
	3-Year EPS without NRI Growth Rate	98.7
	3-Year FCF Growth Rate	390.9
	3-Year Book Growth Rate	3.5
	Future 3-5Y Total Revenue Growth Rate Estimate	6.15

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	24.06
	9-Day RSI	38.36
	14-Day RSI	43.95
	3-1 Month Momentum %	-2.15
	6-1 Month Momentum %	9.75
	12-1 Month Momentum %	1.58

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.77
	Quick Ratio	1.23
	Cash Ratio	0.22
	Days Inventory	249.61
	Days Sales Outstanding	87.94
	Days Payable	237.69

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.23
	Dividend Payout Ratio	0.05
	3-Year Dividend Growth Rate	26
	Forward Dividend Yield %	0.23
	5-Year Yield-on-Cost %	0.36
	Shareholder Yield %	2.15

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	71.59
	Operating Margin %	23.93
	Net Margin %	8.15
	EBITDA Margin %	16.56
	FCF Margin %	12.49
	OCF Margin %	20.61
	ROE %	14.12
	ROA %	7.43
	ROIC %	21.32
	ROC (Joel Greenblatt) %	30.91
	ROCE %	18.46
	Years of Profitability over Past 10-Year	9

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	45.61
	Forward PE Ratio	26.75
	PE Ratio without NRI	21.49
	Shiller PE Ratio	73.97
	Price-to-Owner-Earnings	63.25
	PEG Ratio	7.41
	PS Ratio	3.72
	PB Ratio	5.91
	Price-to-Tangible-Book	7.76
	Price-to-Free-Cash-Flow	29.76
	Price-to-Operating-Cash-Flow	18.02
	EV-to-EBIT	27.92
	EV-to-Forward-EBIT	9.64
	EV-to-EBITDA	22.12
	EV-to-Forward-EBITDA	122.18
	EV-to-Revenue	3.67
	EV-to-Forward-Revenue	33.23
	EV-to-FCF	29.84
	Price-to-GF-Value	1.11
	Price-to-Projected-FCF	6.8
	Price-to-DCF (Earnings Based)	0.9
	Price-to-DCF (FCF Based)	1.25
	Price-to-Median-PS-Value	2.06
	Price-to-Graham-Number	2.72
	Price-to-Net-Current-Asset-Value	32.61
	Earnings Yield (Greenblatt) %	3.59
	FCF Yield %	3.38
	Forward Rate of Return (Yacktman) %	2.88

Financials (Next Earnings Date:2026-08-03)

Annual Quarterly TTM

NSE:GLENMARK's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Glenmark Pharmaceuticals Ltd Executives

Details

GF Value™: ₹1985.29

NSE:GLENMARK

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Medium warning signs with GLENMARK. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ₹)	167,114.03
	EPS (TTM) (₹)	48.24
	Beta	0.8992
	3-Year Sharpe Ratio	1.14
	3-Year Sortino Ratio	2.27
	Volatility %	29.35
	14-Day RSI	43.95
	14-Day ATR (₹)	53.768594
	20-Day SMA (₹)	2234.295
	12-1 Month Momentum %	1.58
	52-Week Range (₹)	1792.6 - 2474
	Shares Outstanding (Mil)	282.2

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Glenmark Pharmaceuticals Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Glenmark Pharmaceuticals Ltd Stock Events

Financials Calendars

Event	Date	Price (₹)
Second quarter earnings conference call for 2027	2026-11-17 08:30	In 118 days
Second quarter earnings results for 2027	2026-11-13	In 113 days
General meeting for 2026	2026-09-25 14:00	In 65 days
Annual report for 2026	2026-08-28	In 36 days
First quarter earnings conference call for 2027	2026-08-03 08:30	In 12 days
First quarter earnings results for 2027	2026-08-03	In 11 days
Fourth quarter earnings conference call for 2026	2026-06-01 08:30	2,274.90 (-5.21%)
Fourth quarter earnings results for 2026	2026-06-01	2,274.90 (-5.21%)
Third quarter earnings conference call for 2026	2026-02-02 08:30	1,940.00 (-3.53%)
Third quarter earnings results for 2026	2026-01-30	1,985.60 (-0.84%)

Show

Entries

Glenmark Pharmaceuticals Ltd Frequently Asked Questions

What is Glenmark Pharmaceuticals Ltd(NSE:GLENMARK)'s stock price today?

The current price of NSE:GLENMARK is ₹2199.90. The 52 week high of NSE:GLENMARK is ₹2474.00 and 52 week low is ₹1792.60.

When is next earnings date of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK)?

The next earnings date of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) is 2026-08-03.

Does Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) pay dividends? If so, how much?

The Dividend Yield % of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) is 0.23% (As of Today), Highest Dividend Payout Ratio of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) was 0.19. The lowest was 0.05. And the median was 0.07. The Forward Dividend Yield % of Glenmark Pharmaceuticals Ltd(NSE:GLENMARK) is 0.23%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity	2026-03-04
	Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe	2025-12-01
	Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials	2025-10-24
	Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials	2025-09-02
	Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)	2025-08-19
	Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)	2025-04-01
	Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials	2025-03-03
	Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial	2025-02-27
	Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules	2025-01-22
	Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials	2023-01-10

10/Page

Articles on Glenmark Pharmaceuticals Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.